Wockhardt has initiated the manufacturing of Oxford AstraZeneca vaccine at its manufacturing plant in the UK, said Habil F Khorakiwala, Chairman and Group CEO of the pharma company on Thursday.
Speaking in an interview with CNBC-TV18, Khorakiwala said, “We have initiated the manufacturing of Oxford Astrazeneca vaccine in our manufacturing facility (UK plant) and about 2-3 million doses already manufactures and is waiting for testing.”
Wockhardt will be supplying 90-100 million doses as per its contract with the UK government, he added.
“We have manufactured about 2.5-3 million vaccines which is awaiting quality control check and once it is done by Astrazeneca, it will be released,” said Khorakiwala.
Khorakiwala said that his company would look to manufacture vaccine in India along with fill and finish.
“Our objective is to meet the needs of vaccine manufacturing.”
Watch the video for more